The Effect of Chronic Iloperidone Treatment on Cytochrome P450 Expression and Activity in the Rat Liver: Involvement of Neuroendocrine Mechanisms

• Published in: International journal of molecular sciences Vol. 22; no. 16; p. 8447
• Main Authors: Danek, Przemysław J., Kuban, Wojciech, Daniel, Władysława A.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 06-08-2021; MDPI
• Subjects: Biocompatibility; Corticosterone; CYP1A protein; CYP1A2 protein; Cytochrome; Cytochrome P450; cytochrome P450 expression/activity; Cytochromes P450; Dopamine; Drug metabolism; Drugs; Enzymes; Gene expression; Growth hormone-releasing hormone; Growth hormones; hormone levels; Hormones; iloperidone; Interleukin 2; Interleukin 6; Liver; Mental disorders; Metabolism; mRNA; Nervous system; neuroendocrine regulation; Neuroendocrine system; Patients; Pharmacokinetics; Pharmacology; prolonged administration; Proteins; rat liver; Schizophrenia; Serotonin; Testosterone; Thyroid gland; Toxicity
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms22168447

In order to achieve a desired therapeutic effect in schizophrenia patients and to maintain their mental wellbeing, pharmacological therapy needs to be continued for a long time, usually from the onset of symptoms and for the rest of the patients’ lives. The aim of our present research is to find out the in vivo effect of chronic treatment with atypical neuroleptic iloperidone on the expression and activity of cytochrome P450 (CYP) in rat liver. Male Wistar rats received a once-daily intraperitoneal injection of iloperidone (1 mg/kg) for a period of two weeks. Twenty-four hours after the last dose, livers were excised to study cytochrome P450 expression (mRNA and protein) and activity, pituitaries were isolated to determine growth hormone-releasing hormone (GHRH), and blood was collected for measuring serum concentrations of hormones and interleukin. The results showed a broad spectrum of changes in the expression and activity of liver CYP enzymes, which are important for drug metabolism (CYP1A, CYP2B, CYP2C, and CYP3A) and xenobiotic toxicity (CYP2E1). Iloperidone decreased the expression and activity of CYP1A2, CP2B1/2, CYP2C11, and CYP3A1/2 enzymes but increased that of CYP2E1. The CYP2C6 enzyme remained unchanged. At the same time, the level of GHRH, GH, and corticosterone decreased while that of T3 increased, with no changes in IL-2 and IL-6. The presented results indicate neuroendocrine regulation of the investigated CYP enzymes during chronic iloperidone treatment and suggest a possibility of pharmacokinetic/metabolic interactions produced by the neuroleptic during prolonged combined treatment with drugs that are substrates of iloperidone-affected CYP enzymes.